Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was s...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical pharmacology Vol. 71; no. 3; pp. 341 - 355
Main Authors Birmingham, Bruce K., Bujac, Sarah R., Elsby, Robert, Azumaya, Connie T., Wei, Cheryl, Chen, Yusong, Mosqueda-Garcia, Rogelio, Ambrose, Helen J.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2015
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Results Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51–130 %) and 55 % (26–91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25–88 %) and 69 % (37–108 %) higher for atorvastatin, 23 % (0–52 %) and 12 % (−0.9–39 %) higher for simvastatin and 28 % (5–56 %) and 34 % (10–64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2 , area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Conclusion Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
AbstractList Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.PURPOSESystemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins.Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.METHODSPlasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed.Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.RESULTSRelative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51-130 %) and 55 % (26-91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25-88 %) and 69 % (37-108 %) higher for atorvastatin, 23 % (0-52 %) and 12 % (-0.9-39 %) higher for simvastatin and 28 % (5-56 %) and 34 % (10-64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively.Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.CONCLUSIONIncreased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods Plasma exposure following single-dose rosuvastatin 20 mg, atorvastatin 40 mg or simvastatin 40 mg was studied in Chinese, Japanese and Caucasian subjects. Plasma concentrations were determined using LC-MS methods. Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Results Relative to Caucasians, geometric mean area under the curve from time zero to time of last quantifiable concentration was 86 % (90 % confidence interval (CI), 51–130 %) and 55 % (26–91 %) higher for rosuvastatin in Chinese and Japanese subjects, respectively, 53 % (25–88 %) and 69 % (37–108 %) higher for atorvastatin, 23 % (0–52 %) and 12 % (−0.9–39 %) higher for simvastatin and 28 % (5–56 %) and 34 % (10–64 %) higher for simvastatin acid. Geometric mean maximum drug concentration was also proportionally higher for each statin. Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2 , area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Conclusion Increased exposure to statins in Asian subjects versus Caucasians may represent a more general class phenomenon than previously recognized.
Author Bujac, Sarah R.
Birmingham, Bruce K.
Wei, Cheryl
Azumaya, Connie T.
Chen, Yusong
Mosqueda-Garcia, Rogelio
Elsby, Robert
Ambrose, Helen J.
Author_xml – sequence: 1
  givenname: Bruce K.
  surname: Birmingham
  fullname: Birmingham, Bruce K.
  email: bkbirm@comcast.net
  organization: AstraZeneca
– sequence: 2
  givenname: Sarah R.
  surname: Bujac
  fullname: Bujac, Sarah R.
  organization: AstraZeneca
– sequence: 3
  givenname: Robert
  surname: Elsby
  fullname: Elsby, Robert
  organization: AstraZeneca
– sequence: 4
  givenname: Connie T.
  surname: Azumaya
  fullname: Azumaya, Connie T.
  organization: AstraZeneca
– sequence: 5
  givenname: Cheryl
  surname: Wei
  fullname: Wei, Cheryl
  organization: AstraZeneca
– sequence: 6
  givenname: Yusong
  surname: Chen
  fullname: Chen, Yusong
  organization: AstraZeneca, PAREXEL International
– sequence: 7
  givenname: Rogelio
  surname: Mosqueda-Garcia
  fullname: Mosqueda-Garcia, Rogelio
  organization: AstraZeneca
– sequence: 8
  givenname: Helen J.
  surname: Ambrose
  fullname: Ambrose, Helen J.
  organization: AstraZeneca
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25673568$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1TAQhS1URG8LD8AGWWLDgsDYuc4Pm-o2KqXSlboA1pGvf6gviR08CVL7NrxpnaYFVAnkxXis74xH5xyRAx-8IeQlg3cMoHyPAJxXGbB1xipg2c0TsmLrnGcM1uyArABylhV1CYfkCHEPwEQN-TNyyEVR5qKoVuTXRT9INdJg6ea0OedUek0_b5tLdsroELrrPsThymGPNHg6XMnYSxW-O29Gp3CWxYDTT4mjHJ1_S-UY4kN3Nwtd_6dXTtNUGzkpiU4uxObuhtNub9SIH6ikqpOI1FibHk6ek6dWdmhe3Ndj8vXj2ZfmU7a9PL9oNttMCajGrM6FlEU6trag63qndZVzJi0IMIqDLXeK7ThoC1bVheZrVZdac1sAGJ6b_Ji8WeYOMfyYDI5t71CZrpPehAlbVogyZ0VV1gl9_Qjdhyn6tN1MiboQTLBEvbqnpl1vdDtE18t43T6YnwC2ACp5iNHY3wiDdg64XQJuU8DtHHB7kzTlI41ys7nBj1G67r9Kvigx_eK_mfjX0v8U3QKew7t6
CitedBy_id crossref_primary_10_1007_s40262_017_0568_7
crossref_primary_10_1038_s41397_019_0122_0
crossref_primary_10_1007_s40268_024_00488_0
crossref_primary_10_1016_j_amjmed_2022_06_018
crossref_primary_10_1038_s41598_020_78231_3
crossref_primary_10_1016_j_beem_2022_101714
crossref_primary_10_12998_wjcc_v10_i5_1557
crossref_primary_10_1007_s00228_018_2420_x
crossref_primary_10_3390_pharmaceutics13050709
crossref_primary_10_1016_j_jacl_2015_06_005
crossref_primary_10_1080_17425255_2019_1681399
crossref_primary_10_1111_bph_17449
crossref_primary_10_1124_dmd_115_067447
crossref_primary_10_2217_pgs_2022_0155
crossref_primary_10_1080_10408347_2018_1439364
crossref_primary_10_1038_s41572_024_00589_9
crossref_primary_10_2217_pgs_16_31
crossref_primary_10_1016_j_ijcard_2016_02_047
crossref_primary_10_1016_j_jpba_2018_07_033
crossref_primary_10_1080_17425255_2021_1876661
crossref_primary_10_3390_cimb45040228
crossref_primary_10_3390_diabetology5040031
crossref_primary_10_1007_s40265_024_02113_5
crossref_primary_10_2217_pgs_2023_0043
crossref_primary_10_38109_2225_1685_2017_1_24_31
crossref_primary_10_2147_PGPM_S482289
crossref_primary_10_1016_j_ejphar_2022_175327
crossref_primary_10_1080_03639045_2017_1414835
crossref_primary_10_2217_pgs_2021_0097
crossref_primary_10_1002_psp4_12582
crossref_primary_10_1089_omi_2016_0114
crossref_primary_10_1097_MOL_0000000000000580
crossref_primary_10_1080_17425255_2020_1801634
crossref_primary_10_1016_j_apsb_2019_01_007
crossref_primary_10_2217_pgs_2016_0065
crossref_primary_10_1007_s00228_017_2318_z
crossref_primary_10_1016_j_xphs_2017_03_027
crossref_primary_10_1007_s13318_022_00798_1
crossref_primary_10_1161_ATV_0000000000000073
crossref_primary_10_1002_jcph_669
crossref_primary_10_1007_s11095_021_03109_6
crossref_primary_10_1016_j_pharmthera_2017_02_029
crossref_primary_10_1093_jac_dkz558
crossref_primary_10_1002_prp2_70073
crossref_primary_10_1111_dom_13849
crossref_primary_10_3389_fnut_2022_868126
crossref_primary_10_1007_s00228_015_1980_2
crossref_primary_10_1097_FPC_0000000000000252
crossref_primary_10_1124_dmd_118_083030
crossref_primary_10_2217_pme_2022_0041
crossref_primary_10_3389_fphar_2021_752960
crossref_primary_10_1007_s00228_021_03233_7
crossref_primary_10_1016_j_xphs_2017_05_008
crossref_primary_10_3390_ijms22062786
crossref_primary_10_1097_FPC_0000000000000260
crossref_primary_10_1002_bdd_2178
crossref_primary_10_1093_eurheartj_ehaa574
crossref_primary_10_4155_bio_2020_0242
crossref_primary_10_1097_FPC_0000000000000308
crossref_primary_10_1186_s12872_025_04611_0
crossref_primary_10_1016_j_bcp_2023_115448
crossref_primary_10_1124_dmd_118_081125
crossref_primary_10_1016_j_ajpc_2021_100157
crossref_primary_10_1124_dmd_117_078931
crossref_primary_10_1124_dmd_117_078816
crossref_primary_10_3109_00498254_2015_1130881
crossref_primary_10_2147_PGPM_S268457
crossref_primary_10_1007_s11938_022_00394_x
crossref_primary_10_1016_j_semnephrol_2018_05_007
crossref_primary_10_2174_1574884714666190408125206
crossref_primary_10_1111_jcpt_12805
crossref_primary_10_2174_0115701611283841231227064343
crossref_primary_10_1002_prp2_890
crossref_primary_10_1124_dmd_115_066795
crossref_primary_10_2217_pgs_2022_0072
crossref_primary_10_2217_pgs_2016_0176
crossref_primary_10_1016_j_ejps_2022_106246
crossref_primary_10_2217_pgs_2018_0168
crossref_primary_10_1111_1755_5922_12214
crossref_primary_10_3390_jpm12121981
crossref_primary_10_1016_j_dmpk_2019_08_004
crossref_primary_10_1007_s10557_020_07070_1
crossref_primary_10_1111_bcp_13207
crossref_primary_10_1093_ehjcvp_pvab018
crossref_primary_10_3390_cells8070763
crossref_primary_10_1186_s40001_024_02109_7
crossref_primary_10_1021_acs_molpharmaceut_5b00474
crossref_primary_10_1089_omi_2023_0122
crossref_primary_10_1111_cts_13185
crossref_primary_10_1016_j_xphs_2017_04_074
crossref_primary_10_1038_s41598_020_65843_y
crossref_primary_10_3390_genes15010099
crossref_primary_10_3390_ijms22073530
crossref_primary_10_2217_pme_2020_0110
crossref_primary_10_58502_DTT_24_0011
crossref_primary_10_1038_s41573_023_00877_1
crossref_primary_10_3390_ph17111411
crossref_primary_10_1136_bmjopen_2020_039034
crossref_primary_10_3389_fgene_2022_836970
crossref_primary_10_3390_pharmaceutics14030501
crossref_primary_10_1016_j_ctcp_2022_101625
crossref_primary_10_1002_cpt_3236
crossref_primary_10_1002_psp4_12837
crossref_primary_10_1016_j_clinbiochem_2024_110707
crossref_primary_10_3390_jcm9010022
crossref_primary_10_1080_17425255_2022_2132932
crossref_primary_10_1007_s00228_014_1800_0
crossref_primary_10_1002_jcph_695
crossref_primary_10_1038_s41598_018_24248_8
crossref_primary_10_3389_fgene_2020_575678
crossref_primary_10_1097_FJC_0000000000000426
crossref_primary_10_3390_jpm9030042
crossref_primary_10_1038_s41598_019_55562_4
crossref_primary_10_1111_jcpt_13299
crossref_primary_10_1097_FPC_0000000000000348
crossref_primary_10_1080_17425255_2018_1482276
crossref_primary_10_3389_fphar_2023_1102810
Cites_doi 10.5551/jat.11.152
10.1016/j.clpt.2005.06.013
10.1185/03007990802312807
10.1016/j.amjcard.2007.01.028
10.1124/dmd.105.007534
10.1111/j.1365-2125.2011.03972.x
10.1038/sj.clpt.6100038
10.1038/sj.clpt.6100428
10.1074/jbc.M103792200
10.2217/pgs.13.115
10.1038/sj.clpt.6100267
10.1038/clpt.2009.79
10.1097/01.fpc.0000230416.82349.90
10.1016/j.clpt.2005.07.006
10.1185/030079907X242809
10.1007/s00228-014-1800-0
10.1038/clpt.2012.221
10.1038/sj.clpt.6100220
10.1016/S0021-9150(00)80175-6
10.1016/j.clinthera.2007.10.005
10.1016/S0149-2918(03)80316-8
10.1038/clpt.2012.163
10.1016/S0149-2918(03)80336-3
10.1097/MJT.0b013e3181f28fb5
10.1016/j.cca.2006.05.010
10.1124/dmd.108.021410
ContentType Journal Article
Copyright Springer-Verlag Berlin Heidelberg 2015
Copyright_xml – notice: Springer-Verlag Berlin Heidelberg 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TK
7U9
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
DOI 10.1007/s00228-014-1801-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
Virology and AIDS Abstracts
ProQuest Health & Medical Collection (NC LIVE)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-1041
EndPage 355
ExternalDocumentID 3595226671
25673568
10_1007_s00228_014_1801_z
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
04C
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3SX
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67N
67Z
6NX
6PF
78A
7RV
7X7
88E
8AO
8FI
8FJ
8FW
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYOK
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADOJX
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADYPR
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
ECT
EIHBH
EIOEI
EJD
EMB
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
MK0
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK6
WK8
WOW
Y6R
YLTOR
Z45
Z7U
Z7V
Z7W
Z81
Z82
Z83
Z87
Z8O
Z8P
Z8Q
Z8U
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7TK
7U9
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
7X8
ID FETCH-LOGICAL-c508t-935aa6a6af9f0d99bdd8321af050ec20f7bc1b20df0fc96d24c97dd2f600e23e3
IEDL.DBID U2A
ISSN 0031-6970
1432-1041
IngestDate Fri Jul 11 03:30:49 EDT 2025
Sat Jul 26 02:33:00 EDT 2025
Mon Jul 21 05:56:15 EDT 2025
Thu Apr 24 23:00:19 EDT 2025
Tue Jul 01 01:41:12 EDT 2025
Fri Feb 21 02:34:24 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Caucasian
Pharmacogenetics
Pharmacokinetics
Asian
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-935aa6a6af9f0d99bdd8321af050ec20f7bc1b20df0fc96d24c97dd2f600e23e3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 25673568
PQID 1655965151
PQPubID 47171
PageCount 15
ParticipantIDs proquest_miscellaneous_1657316879
proquest_journals_1655965151
pubmed_primary_25673568
crossref_primary_10_1007_s00228_014_1801_z
crossref_citationtrail_10_1007_s00228_014_1801_z
springer_journals_10_1007_s00228_014_1801_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-03-01
PublicationDateYYYYMMDD 2015-03-01
PublicationDate_xml – month: 03
  year: 2015
  text: 2015-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle European journal of clinical pharmacology
PublicationTitleAbbrev Eur J Clin Pharmacol
PublicationTitleAlternate Eur J Clin Pharmacol
PublicationYear 2015
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References TironaRGLeakeBFMerinoGKimRBPolymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-AmericansJ Biol Chem2001276356693567510.1074/jbc.M1037922001:CAS:528:DC%2BD3MXntFahsb4%3D11477075
LeeHKHuMLuiSSHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patientsPharmacogenomics2013141283129410.2217/pgs.13.1151:CAS:528:DC%2BC3sXht1Chtb7M23930675
TzengTBSchneckDWBirminghamBKMitchellPDZhangHMartinPDKungLPPopulation pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemiaCurr Med Res Opin2008242575258510.1185/030079908023128071:CAS:528:DC%2BD1cXhtlKit7rK18674408
Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103
KeskitaloJEZolkOFrommMFKurkinenKJNeuvonenPJNiemiMABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20098619720310.1038/clpt.2009.791:CAS:528:DC%2BD1MXovFOrtrg%3D19474787
AllredAJBowenCJParkJWPengBWilliamsDDWireMBLeeEEltrombopag increases plasma rosuvastatin exposure in healthy volunteersBr J Clin Pharmacol20117232132910.1111/j.1365-2125.2011.03972.x31626611:CAS:528:DC%2BC3MXhtV2qtrvE21434975
MartinPDWarwickMJDaneALBrindleyCShortTAbsolute oral bioavailability of rosuvastatin in healthy white adult male volunteersClin Ther2003252553256310.1016/S0149-2918(03)80316-81:CAS:528:DC%2BD3sXpvVGksLk%3D14667956
PasanenMKNeuvonenMNeuvonenPJNiemiMSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenet Genomics20061687387910.1097/01.fpc.0000230416.82349.901:CAS:528:DC%2BD28Xht1SmtrvP17108811
PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673310.1038/sj.clpt.61002201:CAS:528:DC%2BD2sXht1ymu7jM17473846
ChoiJHLeeMGChoJYLeeJEKimKHParkKInfluence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in KoreansClin Pharmacol Ther20088325125710.1038/sj.clpt.61002671:CAS:528:DC%2BD1cXitFKjtLY%3D17568401
LauYYHuangYFrassettoLBenetLZEffect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteersClin Pharmacol Ther20078119420410.1038/sj.clpt.61000381:CAS:528:DC%2BD2sXisFyrtLY%3D17192770
ZhuJRTomlinsonBRoYMSimKHLeeYTSriratanasathavornCA randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Curr Med Res Opin2007233055306810.1185/030079907X2428091:CAS:528:DC%2BD1cXhslOksLc%3D18196620
MartinPDWarwickMJDaneALHillSJGilesPBPhillipsPJLenzEMetabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteersClin Ther2003252822283510.1016/S0149-2918(03)80336-31:CAS:528:DC%2BD2cXhtVynsQ%3D%3D14693307
WarwickMJDaneALRazaASchneckDWSingle- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis20001513910.1016/S0021-9150(00)80175-6(Abstract)
LeeERyanSBirminghamBZalikowskiJMarchRAmbroseHMooreRLeeCChenYSchneckDRosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClin Pharmacol Ther20057833034110.1016/j.clpt.2005.06.0131:CAS:528:DC%2BD2MXhtVGrsLfF16198652
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ (2015) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0
Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94:37–51
Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 19:164–173
Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, Ikeda Y, Nii M (2004) Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11:152–158
KitamuraSMaedaKWangYSugiyamaYInvolvement of multiple transporters in the hepatobiliary transport of rosuvastatinDrug Metab Dispos2008362014202310.1124/dmd.108.0214101:CAS:528:DC%2BD1cXhtF2jtLbJ18617601
TironaRGEthnic differences in statin dispositionClin Pharmacol Ther20057831131610.1016/j.clpt.2005.07.0061:CAS:528:DC%2BD2MXhtVGrsLfK16198649
DeedwaniaPCGuptaMSteinMYcasJGoldAIRIS Study GroupComparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)Am J Cardiol2007991538154310.1016/j.amjcard.2007.01.0281:CAS:528:DC%2BD2sXlvVaktLk%3D17531577
ElsbyRHilgendorfCFennerKUnderstanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1Clin Pharmacol Ther20129258459810.1038/clpt.2012.1631:CAS:528:DC%2BC38XhsFChsbjL23047648
LiYJiangXLanKZhangRLiXJiangQPharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover studyClin Ther2007292194220310.1016/j.clinthera.2007.10.0051:CAS:528:DC%2BD2sXhsVygtrfJ18042475
HuangLWangYGrimmSATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance proteinDrug Metab Dispos20063473874210.1124/dmd.105.0075341:CAS:528:DC%2BD28Xks1Sks7c%3D16415124
KimKBirminghamBKAzumayaCTZalikowskiJChenYSchneckDIncreased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjectsClin Pharmacol Ther200883S1410.1038/sj.clpt.6100428(Abstract)
K Kim (1801_CR7) 2008; 83
JH Choi (1801_CR11) 2008; 83
E Lee (1801_CR2) 2005; 78
PD Martin (1801_CR9) 2003; 25
AJ Allred (1801_CR25) 2011; 72
PC Deedwania (1801_CR3) 2007; 99
L Huang (1801_CR14) 2006; 34
MJ Warwick (1801_CR5) 2000; 151
1801_CR26
RG Tirona (1801_CR17) 2005; 78
1801_CR20
S Kitamura (1801_CR12) 2008; 36
RG Tirona (1801_CR13) 2001; 276
JR Zhu (1801_CR4) 2007; 23
MK Pasanen (1801_CR22) 2007; 82
PD Martin (1801_CR10) 2003; 25
TB Tzeng (1801_CR8) 2008; 24
HK Lee (1801_CR21) 2013; 14
R Elsby (1801_CR18) 2012; 92
Y Li (1801_CR6) 2007; 29
1801_CR19
MK Pasanen (1801_CR24) 2006; 16
YY Lau (1801_CR23) 2007; 81
1801_CR16
1801_CR1
JE Keskitalo (1801_CR15) 2009; 86
23047648 - Clin Pharmacol Ther. 2012 Nov;92 (5):584-98
25630984 - Eur J Clin Pharmacol. 2015 Mar;71(3):329-40
14693307 - Clin Ther. 2003 Nov;25(11):2822-35
14667956 - Clin Ther. 2003 Oct;25(10):2553-63
19474787 - Clin Pharmacol Ther. 2009 Aug;86(2):197-203
17108811 - Pharmacogenet Genomics. 2006 Dec;16(12 ):873-9
20975528 - Am J Ther. 2012 May;19(3):164-73
18196620 - Curr Med Res Opin. 2007 Dec;23(12):3055-68
11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75
18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85
17568401 - Clin Pharmacol Ther. 2008 Feb;83(2):251-7
15256766 - J Atheroscler Thromb. 2004;11(3):152-8
16415124 - Drug Metab Dispos. 2006 May;34(5):738-42
17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33
23930675 - Pharmacogenomics. 2013 Aug;14 (11):1283-94
18617601 - Drug Metab Dispos. 2008 Oct;36(10 ):2014-23
16784736 - Clin Chim Acta. 2006 Nov;373(1-2):99-103
16198649 - Clin Pharmacol Ther. 2005 Oct;78(4):311-6
16198652 - Clin Pharmacol Ther. 2005 Oct;78(4):330-41
17531577 - Am J Cardiol. 2007 Jun 1;99(11):1538-43
17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204
23443754 - Clin Pharmacol Ther. 2013 Jul;94(1):37-51
21434975 - Br J Clin Pharmacol. 2011 Aug;72 (2):321-9
18042475 - Clin Ther. 2007 Oct;29(10):2194-203
References_xml – reference: KeskitaloJEZolkOFrommMFKurkinenKJNeuvonenPJNiemiMABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20098619720310.1038/clpt.2009.791:CAS:528:DC%2BD1MXovFOrtrg%3D19474787
– reference: TzengTBSchneckDWBirminghamBKMitchellPDZhangHMartinPDKungLPPopulation pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemiaCurr Med Res Opin2008242575258510.1185/030079908023128071:CAS:528:DC%2BD1cXhtlKit7rK18674408
– reference: TironaRGEthnic differences in statin dispositionClin Pharmacol Ther20057831131610.1016/j.clpt.2005.07.0061:CAS:528:DC%2BD2MXhtVGrsLfK16198649
– reference: LauYYHuangYFrassettoLBenetLZEffect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteersClin Pharmacol Ther20078119420410.1038/sj.clpt.61000381:CAS:528:DC%2BD2sXisFyrtLY%3D17192770
– reference: LeeHKHuMLuiSSHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patientsPharmacogenomics2013141283129410.2217/pgs.13.1151:CAS:528:DC%2BC3sXht1Chtb7M23930675
– reference: Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ (2015) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol doi: 10.1007/s00228-014-1800-0
– reference: Mabuchi H, Nohara A, Higashikata T, Ueda K, Bujo H, Matsushima T, Ikeda Y, Nii M (2004) Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 11:152–158
– reference: PasanenMKNeuvonenMNeuvonenPJNiemiMSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenet Genomics20061687387910.1097/01.fpc.0000230416.82349.901:CAS:528:DC%2BD28Xht1SmtrvP17108811
– reference: HuangLWangYGrimmSATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance proteinDrug Metab Dispos20063473874210.1124/dmd.105.0075341:CAS:528:DC%2BD28Xks1Sks7c%3D16415124
– reference: LeeERyanSBirminghamBZalikowskiJMarchRAmbroseHMooreRLeeCChenYSchneckDRosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClin Pharmacol Ther20057833034110.1016/j.clpt.2005.06.0131:CAS:528:DC%2BD2MXhtVGrsLfF16198652
– reference: KimKBirminghamBKAzumayaCTZalikowskiJChenYSchneckDIncreased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjectsClin Pharmacol Ther200883S1410.1038/sj.clpt.6100428(Abstract)
– reference: MartinPDWarwickMJDaneALHillSJGilesPBPhillipsPJLenzEMetabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteersClin Ther2003252822283510.1016/S0149-2918(03)80336-31:CAS:528:DC%2BD2cXhtVynsQ%3D%3D14693307
– reference: Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103
– reference: ZhuJRTomlinsonBRoYMSimKHLeeYTSriratanasathavornCA randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Curr Med Res Opin2007233055306810.1185/030079907X2428091:CAS:528:DC%2BD1cXhslOksLc%3D18196620
– reference: PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673310.1038/sj.clpt.61002201:CAS:528:DC%2BD2sXht1ymu7jM17473846
– reference: LiYJiangXLanKZhangRLiXJiangQPharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover studyClin Ther2007292194220310.1016/j.clinthera.2007.10.0051:CAS:528:DC%2BD2sXhsVygtrfJ18042475
– reference: ElsbyRHilgendorfCFennerKUnderstanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1Clin Pharmacol Ther20129258459810.1038/clpt.2012.1631:CAS:528:DC%2BC38XhsFChsbjL23047648
– reference: KitamuraSMaedaKWangYSugiyamaYInvolvement of multiple transporters in the hepatobiliary transport of rosuvastatinDrug Metab Dispos2008362014202310.1124/dmd.108.0214101:CAS:528:DC%2BD1cXhtF2jtLbJ18617601
– reference: TironaRGLeakeBFMerinoGKimRBPolymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-AmericansJ Biol Chem2001276356693567510.1074/jbc.M1037922001:CAS:528:DC%2BD3MXntFahsb4%3D11477075
– reference: ChoiJHLeeMGChoJYLeeJEKimKHParkKInfluence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in KoreansClin Pharmacol Ther20088325125710.1038/sj.clpt.61002671:CAS:528:DC%2BD1cXitFKjtLY%3D17568401
– reference: Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 19:164–173
– reference: DeedwaniaPCGuptaMSteinMYcasJGoldAIRIS Study GroupComparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)Am J Cardiol2007991538154310.1016/j.amjcard.2007.01.0281:CAS:528:DC%2BD2sXlvVaktLk%3D17531577
– reference: AllredAJBowenCJParkJWPengBWilliamsDDWireMBLeeEEltrombopag increases plasma rosuvastatin exposure in healthy volunteersBr J Clin Pharmacol20117232132910.1111/j.1365-2125.2011.03972.x31626611:CAS:528:DC%2BC3MXhtV2qtrvE21434975
– reference: MartinPDWarwickMJDaneALBrindleyCShortTAbsolute oral bioavailability of rosuvastatin in healthy white adult male volunteersClin Ther2003252553256310.1016/S0149-2918(03)80316-81:CAS:528:DC%2BD3sXpvVGksLk%3D14667956
– reference: Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94:37–51
– reference: WarwickMJDaneALRazaASchneckDWSingle- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis20001513910.1016/S0021-9150(00)80175-6(Abstract)
– ident: 1801_CR1
  doi: 10.5551/jat.11.152
– volume: 78
  start-page: 330
  year: 2005
  ident: 1801_CR2
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2005.06.013
– volume: 24
  start-page: 2575
  year: 2008
  ident: 1801_CR8
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007990802312807
– volume: 99
  start-page: 1538
  year: 2007
  ident: 1801_CR3
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2007.01.028
– volume: 34
  start-page: 738
  year: 2006
  ident: 1801_CR14
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.105.007534
– volume: 72
  start-page: 321
  year: 2011
  ident: 1801_CR25
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2011.03972.x
– volume: 81
  start-page: 194
  year: 2007
  ident: 1801_CR23
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100038
– volume: 83
  start-page: S14
  year: 2008
  ident: 1801_CR7
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100428
– volume: 276
  start-page: 35669
  year: 2001
  ident: 1801_CR13
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M103792200
– volume: 14
  start-page: 1283
  year: 2013
  ident: 1801_CR21
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.13.115
– volume: 83
  start-page: 251
  year: 2008
  ident: 1801_CR11
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100267
– volume: 86
  start-page: 197
  year: 2009
  ident: 1801_CR15
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.79
– volume: 16
  start-page: 873
  year: 2006
  ident: 1801_CR24
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/01.fpc.0000230416.82349.90
– volume: 78
  start-page: 311
  year: 2005
  ident: 1801_CR17
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2005.07.006
– volume: 23
  start-page: 3055
  year: 2007
  ident: 1801_CR4
  publication-title: Curr Med Res Opin
  doi: 10.1185/030079907X242809
– ident: 1801_CR16
  doi: 10.1007/s00228-014-1800-0
– ident: 1801_CR26
  doi: 10.1038/clpt.2012.221
– volume: 82
  start-page: 726
  year: 2007
  ident: 1801_CR22
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100220
– volume: 151
  start-page: 39
  year: 2000
  ident: 1801_CR5
  publication-title: Atherosclerosis
  doi: 10.1016/S0021-9150(00)80175-6
– volume: 29
  start-page: 2194
  year: 2007
  ident: 1801_CR6
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2007.10.005
– volume: 25
  start-page: 2553
  year: 2003
  ident: 1801_CR9
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(03)80316-8
– volume: 92
  start-page: 584
  year: 2012
  ident: 1801_CR18
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.163
– volume: 25
  start-page: 2822
  year: 2003
  ident: 1801_CR10
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(03)80336-3
– ident: 1801_CR19
  doi: 10.1097/MJT.0b013e3181f28fb5
– ident: 1801_CR20
  doi: 10.1016/j.cca.2006.05.010
– volume: 36
  start-page: 2014
  year: 2008
  ident: 1801_CR12
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.108.021410
– reference: 16415124 - Drug Metab Dispos. 2006 May;34(5):738-42
– reference: 11477075 - J Biol Chem. 2001 Sep 21;276(38):35669-75
– reference: 16784736 - Clin Chim Acta. 2006 Nov;373(1-2):99-103
– reference: 17568401 - Clin Pharmacol Ther. 2008 Feb;83(2):251-7
– reference: 17531577 - Am J Cardiol. 2007 Jun 1;99(11):1538-43
– reference: 20975528 - Am J Ther. 2012 May;19(3):164-73
– reference: 18674408 - Curr Med Res Opin. 2008 Sep;24(9):2575-85
– reference: 15256766 - J Atheroscler Thromb. 2004;11(3):152-8
– reference: 23047648 - Clin Pharmacol Ther. 2012 Nov;92 (5):584-98
– reference: 21434975 - Br J Clin Pharmacol. 2011 Aug;72 (2):321-9
– reference: 23930675 - Pharmacogenomics. 2013 Aug;14 (11):1283-94
– reference: 16198649 - Clin Pharmacol Ther. 2005 Oct;78(4):311-6
– reference: 14693307 - Clin Ther. 2003 Nov;25(11):2822-35
– reference: 19474787 - Clin Pharmacol Ther. 2009 Aug;86(2):197-203
– reference: 17473846 - Clin Pharmacol Ther. 2007 Dec;82(6):726-33
– reference: 16198652 - Clin Pharmacol Ther. 2005 Oct;78(4):330-41
– reference: 17108811 - Pharmacogenet Genomics. 2006 Dec;16(12 ):873-9
– reference: 18196620 - Curr Med Res Opin. 2007 Dec;23(12):3055-68
– reference: 14667956 - Clin Ther. 2003 Oct;25(10):2553-63
– reference: 17192770 - Clin Pharmacol Ther. 2007 Feb;81(2):194-204
– reference: 23443754 - Clin Pharmacol Ther. 2013 Jul;94(1):37-51
– reference: 18042475 - Clin Ther. 2007 Oct;29(10):2194-203
– reference: 18617601 - Drug Metab Dispos. 2008 Oct;36(10 ):2014-23
– reference: 25630984 - Eur J Clin Pharmacol. 2015 Mar;71(3):329-40
SSID ssj0015903
Score 2.4641387
Snippet Purpose Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased...
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 341
SubjectTerms Adolescent
Adult
Aged
Asian Continental Ancestry Group - genetics
Asian people
Atorvastatin Calcium - adverse effects
Atorvastatin Calcium - blood
Atorvastatin Calcium - pharmacokinetics
ATP Binding Cassette Transporter, Sub-Family G, Member 2
ATP-Binding Cassette Transporters - genetics
Biomedical and Life Sciences
Biomedicine
European Continental Ancestry Group - genetics
Female
Genotype
Genotype & phenotype
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics
Male
Middle Aged
Neoplasm Proteins - genetics
Organic Anion Transporters - genetics
Pharmacokinetics and Disposition
Pharmacology
Pharmacology/Toxicology
Polymorphism
Polymorphism, Single Nucleotide - genetics
Rosuvastatin Calcium - adverse effects
Rosuvastatin Calcium - blood
Rosuvastatin Calcium - pharmacokinetics
Simvastatin - adverse effects
Simvastatin - analogs & derivatives
Simvastatin - blood
Simvastatin - pharmacokinetics
Solute Carrier Organic Anion Transporter Family Member 1b1
Statins
White people
Young Adult
SummonAdditionalLinks – databaseName: ProQuest Health & Medical Collection (NC LIVE)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgvPCCGNfAQEZCe4Ba2ImT1LxMXcUYiMskNqlvkeOLVG1NytIidf-Gf8o5zqWgiSkPSRTbsXJOfD7fvo-Q12WSQdg1no0hHjCk0GLaopq7ks4K6zi3uBv567fs-Ex-nqWzbsCt6ZZV9m1iaKhtbXCM_J3IAPuibrc4WP5kqBqFs6udhMZtcgepy9Cr89nQ4YJIzTvSXcEylQ-zmjyQiMbIzSwkE9BIs6t_49I1sHltojTEn6P75F4HHOmktfQuueWqB2T_pGWe3ozo6XYjVTOi-_Rky0m9eUh-fwq7IWnt6eRw-jGmurL0x5fpd3Eo6LK-2Cxq-ODzZtHQuqLLLu85QFAsD7NBrde_NO4_mlcjil31_i6U1cwX23sztxTOU42KauB_IcUkXDXrEkd-mvdUU4PInbYrSg4ekbOjD6fTY9apMzADoG7FVJJqncHhledWqdJaVD3SnqfcmZj7vDSijLn13BuV2VgalVsbe4BYLk5c8pjsVHXlnhIqpbdClgBGx6WUGsKHcmkis7ETmdZGR4T3tilMR12OChoXxUC6HMxZgDkLNGdxFZE3Q5Zly9txU-K93uBF9ws3xdbhIvJqeAw_H86o6MrV65AmKH_lKiJPWkcZ3gZYMk_SbByRt73n_FX4_6ry7OaqPCd3AbGl7SK4PbKzuly7F4CKVuXL4Pp_AO34Ci8
  priority: 102
  providerName: ProQuest
Title Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
URI https://link.springer.com/article/10.1007/s00228-014-1801-z
https://www.ncbi.nlm.nih.gov/pubmed/25673568
https://www.proquest.com/docview/1655965151
https://www.proquest.com/docview/1657316879
Volume 71
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfY9sILYnwGRmUktAdoJDtxkpoXlFTtxlepYJXKU-T4Q6rYkmppkbb_hv-Us_NR0AAJ5cGxYl-snO37Xc53h9CLIoxB7Erjj0Ae-DaEli-UzebOmVZUaUKU9Ub-OItPF-zdMlq2ftx1d9q9M0m6nbp3dnOhWkD1ZT6FbdW_3kMHEaju9hzXIkh700HESRtpl_oxT3pT5p9I_C6MbiDMG9ZRJ3Smd9GdFi3itGHvIbqly3voeN6Em74a4rOd91Q9xMd4vgtEfXUf_XjrXCBxZXCajU8CLEqFv3wYf6IZxevqHNR--Mqr-qLGVYnXbd9vgDstPdsNRr39LqzT0aocYqufdzVHq15d7OpypTCUY2HTqMGkcy1Sd1dvC_u7p36NBZYWruPmGMmbB2gxnZyNT_02JYMvAcltfB5GQsRwGW6I4rxQyqY6EoZERMuAmKSQtAiIMsRIHquASZ4oFRjAVToIdfgQ7ZdVqR8jzJhRlBWAQEcFYwJkBtdRyOKRprEQUniIdLzJZRuv3KbNOM_7SMuOnTmwM7fszK899LLvsm6Cdfyr8VHH8Lxdt3VOY9CwbHZ46qHn_WNYcdaMIkpdbV0bl-4r4R561EyU_m0AIJMwikceetXNnF-I_20oT_6r9VN0G1Bb1ByEO0L7m8utfgbIaFMM0F6yTAboIJ1m2cyWJ1_fT6DMJrP554FbJz8B4r4MsQ
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGeIAXxJ2MAUaCPUAj7MRJGiQ0dYXRsm5MopP6FhzbkaqtSSEtqPs3_AF-I-c4l4Im9jb1oY1qO5bOsc_ny_k-Ql6kfghhV2VuF-KBixRartSo5h4Lo7k2jGnMRj48Cgcn4tMkmGyQ300uDF6rbOZEO1HrQuEe-RseAvZF3W6-O__momoUnq42EhqVWxyY1U9YspXvhu_Bvi89b__DuD9wa1UBVwEYWbixH0gZwieLM6bjONUa1XpkxgJmlMeyKFU89ZjOWKbiUHtCxZHWXgbQwHi-8aHda-Q6BF6Gi71o0i7wABmwmuSXu2EctaeozJKWesgFzYXLISi45__GwQvg9sLBrI13-7fJrRqo0l7lWXfIhsnvkp3jiul61aHjdeJW2aE79HjNgb26R34NbfYlLTLa2-t_9KjMNf0y6n_me5zOi7PVrAADT8tZSYuczuu6pwB5sT2sBr1e_pCY7zTNOxS3Bpon21Y5na2f1VRT-O5LVHADf7clevZXuUxxp6l8SyVVuFKg1Q2W3fvk5Ers9oBs5kVuHhEqRKa5SAH8dlMhJISr2AS-CLuGh1Iq6RDW2CZRNVU6KnacJS3JszVnAuZM0JzJuUNetVXmFU_IZYW3G4Mn9ZRRJmsHd8jz9m8Y7HiCI3NTLG0ZqzQWxQ55WDlK-zbArpEfhF2HvG4856_G_9eVrcu78ozcGIwPR8loeHTwmNwEtBhUF_C2yebi-9I8AUS2SJ_aYUDJ16sed38AXrdIkA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEHcKA4wEe4BGs3OtkdDUdisrG6WCTdpbcHyRKtakkBbU_Rv-Br-Oc3IraGJvUx6SKLZj6Rz7fPbx-Q4hLxIvBLOrrNMFe-AghZYjNWZzF77RXBvGNEYjfxiHByf--9PgdIP8rmNh8FhlPScWE7XOFO6R7_AQsC_m7eY7tjoWMdkb7s6_OZhBCj2tdTqNUkUOzeonLN_yt6M9kPVL1x3uHw8OnCrDgKMAmCwc4QVShnBZYZkWItEaM_dIywJmlMtslCieuExbZpUItesrEWntWoAJxvWMB-1eI5sRropaZLO_P558anwYgWAV5S93QhE1PlVWUJi6yAzNfYeDiXDO_7WKF6DuBTdtYf2Gt8jNCrbSXqlnt8mGSe-Q7UnJe73q0ON1GFfeodt0smbEXt0lv0ZFLCbNLO31B-9cKlNNPx8NPvI-p_PsbDXLQNzTfJbTLKXzqu5XAMDYHlaDXi9_SIx-mqYdihsF9VvRVj6drd_VVFO4DyTmcwPtL0r0iqd8meC-U_6GSqpw3UDL8yy798jJlUjuPmmlWWoeEur7VnM_ASjcTXxfgvESJvD8sGt4KKWSbcJq2cSqIk7H_B1ncUP5XIgzBnHGKM74vE1eNVXmJWvIZYW3aoHH1QSSx2t1b5PnzWcY-ujPkanJlkWZIu9YJNrkQakozd8AyUZeEHbb5HWtOX81_r-uPLq8K8_IdRhz8dFofPiY3ADoGJSn8bZIa_F9aZ4APFskT6txQMmXqx56fwA_P04r
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+ABCG2+and+SLCO1B1+polymorphisms+on+pharmacokinetics+of+rosuvastatin%2C+atorvastatin+and+simvastatin+acid+in+Caucasian+and+Asian+subjects%3A+a+class+effect%3F&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Birmingham%2C+Bruce+K&rft.au=Bujac%2C+Sarah+R&rft.au=Elsby%2C+Robert&rft.au=Azumaya%2C+Connie+T&rft.date=2015-03-01&rft.issn=1432-1041&rft.eissn=1432-1041&rft.volume=71&rft.issue=3&rft.spage=341&rft_id=info:doi/10.1007%2Fs00228-014-1801-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon